Versor Investments LP Invests $2.26 Million in Ralliant Corporation $RAL

Versor Investments LP acquired a new position in Ralliant Corporation (NYSE:RAL) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 51,703 shares of the company’s stock, valued at approximately $2,261,000. Ralliant makes up approximately 0.4% of Versor Investments LP’s holdings, making the stock its 22nd biggest holding.

Other hedge funds have also recently added to or reduced their stakes in the company. Nordea Investment Management AB acquired a new position in shares of Ralliant in the 2nd quarter valued at about $29,477,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Ralliant during the second quarter worth approximately $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Ralliant during the second quarter valued at approximately $1,410,000. JPMorgan Chase & Co. acquired a new position in Ralliant in the 2nd quarter valued at approximately $18,494,000. Finally, Allspring Global Investments Holdings LLC increased its stake in Ralliant by 5,269.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 317,038 shares of the company’s stock valued at $14,000,000 after buying an additional 311,134 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Barclays decreased their target price on shares of Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a research note on Monday. Royal Bank Of Canada reduced their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday. Oppenheimer lowered their target price on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday. Truist Financial cut their price target on Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research note on Friday. Finally, Vertical Research upgraded Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a report on Friday. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.50.

Ralliant Stock Performance

Shares of RAL opened at $41.16 on Tuesday. The company has a market capitalization of $4.64 billion and a PE ratio of 32.41. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58. Ralliant Corporation has a one year low of $37.27 and a one year high of $57.02. The company’s fifty day moving average price is $51.37 and its 200 day moving average price is $46.67.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.02. The business had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Ralliant’s dividend payout ratio is 15.75%.

Insider Buying and Selling at Ralliant

In other news, SVP Amir A. Kazmi bought 2,545 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The shares were acquired at an average cost of $39.27 per share, with a total value of $99,942.15. Following the completion of the transaction, the senior vice president directly owned 39,699 shares in the company, valued at $1,558,979.73. This represents a 6.85% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kevin E. Bryant purchased 1,250 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were purchased at an average price of $39.97 per share, for a total transaction of $49,962.50. Following the completion of the purchase, the director directly owned 4,653 shares of the company’s stock, valued at approximately $185,980.41. This trade represents a 36.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Key Headlines Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Senior insiders increased holdings — SVP Amir Kazmi bought 2,545 shares (~$39.27 avg) and Director Kevin Bryant bought 1,250 shares (~$39.97 avg). Insider purchases typically signal management confidence and can support near‑term demand. Read More.
• Positive Sentiment: Vertical Research upgraded RAL from Hold to Buy, which can attract buyers and improve sentiment among retail and institutional investors. Read More.
• Neutral Sentiment: Barclays lowered its price target from $60 to $52 but maintained an Overweight rating — still implies meaningful upside from current levels, though the cut reduces near‑term bullishness. Read More.
• Neutral Sentiment: Citigroup trimmed its price target to $51, another analyst downward adjustment but still above current trading, reflecting mixed analyst views rather than a consensus sell signal. Read More.
• Neutral Sentiment: Earnings call takeaways: TipRanks notes Ralliant’s strong cash position but margin pressure — the Q4 beat and FY26 guidance remain relevant for fundamentals, though margin trends could temper enthusiasm. Read More.
• Negative Sentiment: Multiple law firms (Kirby McInerney, Bragar Eagel & Squire, Kaplan Fox) have launched or publicized investigations into possible securities‑law violations at Ralliant. This is the largest near‑term risk — potential litigation, regulatory action, or reputational damage can increase volatility and put sustained pressure on the share price. Read More. Read More. Read More.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.